'%3e%3cpath%20d='M34.1406%205.85938C30.3906%202.10547%2025.3047%200%2020%200C14.6953%200%209.60938%202.10547%205.85938%205.85938C2.10938%209.61328%200%2014.6953%200%2020C0%2025.3047%202.10547%2030.3906%205.85938%2034.1406C9.61328%2037.8906%2014.6953%2040%2020%2040C25.3047%2040%2030.3906%2037.8945%2034.1406%2034.1406C37.8906%2030.3906%2040%2025.3047%2040%2020C40%2014.6953%2037.8945%209.60938%2034.1406%205.85938ZM37.0117%2023.543H31.1602V13.5391H27.6328V19.9414C28.1211%2020.6914%2028.3711%2021.582%2028.3711%2022.5625V22.625C28.3711%2023.668%2028.1172%2024.6055%2027.6328%2025.4297V26.6094H36.082C33.4883%2032.9375%2027.2891%2037.3789%2020.0039%2037.3789C10.3711%2037.3789%202.62109%2029.6289%202.62109%2020C2.62109%2010.3711%2010.3711%202.62109%2020%202.62109C29.6289%202.62109%2037.3789%2010.3711%2037.3789%2020C37.3789%2021.1484%2037.2617%2022.2656%2037.0508%2023.3477C37.0391%2023.4141%2037.0234%2023.4766%2037.0117%2023.543Z'%20fill='white'/%3e%3cpath%20d='M22.3086%2018.5352C20.4336%2018.125%2019.9531%2017.8398%2019.9766%2017.1836V17.1406C19.9766%2016.6992%2020.3477%2016.2148%2021.4023%2016.2148C22.582%2016.2148%2023.8867%2016.6797%2025.0781%2017.4766L26.8516%2015.0195C25.4453%2013.8906%2023.707%2013.3398%2021.5547%2013.3398C18.5195%2013.3398%2016.4375%2015%2016.4063%2017.4766V17.5352C16.3633%2020.2617%2018.5859%2020.9805%2021.293%2021.6016C23.0391%2021.9766%2023.5703%2022.3164%2023.5703%2022.9609L23.5469%2022.9766C23.5469%2023.3906%2023.2578%2023.7031%2022.7852%2023.8359C22.5742%2023.9062%2022.1289%2023.9727%2021.5156%2023.9727C20.7617%2023.9727%2019.7539%2023.8633%2018.6328%2023.4844C18.0898%2023.2891%2017.4727%2023.0039%2016.8047%2022.6133L20.1406%2026.625C20.2813%2026.6602%2021.0977%2026.8516%2021.7734%2026.8516C25.0039%2026.8516%2027.0859%2025.2461%2027.1094%2022.6328V22.5703C27.1602%2020.1133%2025.2148%2019.1719%2022.3086%2018.5352Z'%20fill='white'/%3e%3cpath%20d='M5.24219%2013.5664V26.6133H8.75391V23.7578L10.2969%2021.9531L14.2031%2026.6133H18.3867L12.3555%2019.5195L17.4023%2013.5664H13.4531L8.75391%2019.0586V13.5664H5.24219Z'%20fill='white'/%3e%3c/g%3e%3cdefs%3e%3cclipPath%20id='clip0_97_2430'%3e%3crect%20width='40'%20height='40'%20fill='white'/%3e%3c/clipPath%3e%3c/defs%3e%3c/svg%3e)
Lifestyle Features
Most Recent
US FDA expands use of Novartis drug for chronic skin condition
Reuters | Updated Oct. 7 - 10:42 a.m. | Save Story
The US Food and Drug Administration has expanded the use of Novartis' drug to treat adults with a chronic skin condition that causes recurring itchy welts, the Swiss drugmaker said on Wednesday.
Life sciences firm Danaher to launch AI-powered autonomous research lab in 2027
Reuters | Updated Oct. 7 - 8:40 a.m. | Save Story
Life sciences company Danaher said on Wednesday it plans to launch its first AI-powered autonomous research lab early next year to make drug discovery and development faster and more efficient.
AI companies run virtual drug trials, aim to improve success of human studies
Deena Beasley, Reuters | Updated Oct. 7 - 4:12 a.m. | Save Story
Novartis' experimental del-desiran for a rare type of muscular dystrophy was expected to be a winner, with the Swiss company's CEO predicting annual peak sales of $5 billion. When a late-stage trial missed its goal last month, shares fell 11%, erasing $30 billion in market value.
Battle of the Broncs returns to Grantsville with a fight against cancer
VideoMadi Vollmer, KSL | Posted Oct. 6 - 1:50 p.m. | Save Story
This year's rodeo, "Ride for the Fight," will honor cancer patients, survivors and loved ones while bringing the community together.
Kenya confirms first Ebola case after man who travelled from Congo dies
Reuters | Updated Oct. 6 - 1:14 p.m. | Save Story
Kenya confirmed its first Ebola case on Tuesday after a Kenyan citizen who had travelled from Democratic Republic of Congo died in Nairobi.
McKesson, CD&R to take infusion therapy provider Option Care private in $5.8 billion deal
Sneha S K, Reuters | Updated Oct. 6 - 10:30 a.m. | Save Story
Drug distributor McKesson and private equity firm Clayton Dubilier & Rice on Tuesday agreed to take infusion therapy provider Option Care Health private in a deal worth about $5.8 billion including debt.
ArriVent's cancer pill fails to 'meaningfully' delay disease progression, shares dive
Christy Santhosh, Reuters | Updated Oct. 6 - 9:06 a.m. | Save Story
ArriVent BioPharma said on Tuesday its oral therapy to treat patients with a rare type of lung cancer did not significantly delay disease progression in a late-stage trial, sending its shares plunging nearly 60% in morning trading.
No plague cases detected in Siberia, Russia says, and locals play down scare
Reuters | Updated Oct. 6 - 7:50 a.m. | Save Story
Russia's health watchdog said on Tuesday that no cases of plague had been detected among anyone who had come into contact with a Siberian plague institute laboratory worker who died last week, and locals said their lives had barely been disrupted.
Could your charging habits spark a fire? Safety tips from firefighters for Fire Prevention Week
VideoEmma Benson, KSL | Updated Oct. 5 - 9:37 p.m. | Save Story
Safe charging habits and proper battery disposal can help prevent fires involving everyday devices, firefighters say.
Genmab, AbbVie blood cancer drug combo cuts risk of progression or death in late-stage study
Sahil Pandey, Reuters | Updated Oct. 5 - 4:09 p.m. | Save Story
Danish biotech firm Genmab and US drugmaker AbbVie said on Monday their combination treatment for patients newly diagnosed with a type of lymphoma reduced the risk of disease progression or death in a late-stage study.
Dozens quarantined in Siberia after plague institute lab worker dies
Andrew Osborn, Reuters | Updated Oct. 5 - 3:22 p.m. | Save Story
A laboratory worker at a plague research institute in Siberia fell ill and died in undisclosed circumstances, prompting authorities to quarantine dozens of people and the head of Russia's health watchdog to fly to the Irkutsk region.
McKesson, CD&R near $5 billion-plus deal to buy Option Care, FT reports
Sahil Pandey, Reuters | Updated Oct. 5 - 3:08 p.m. | Save Story
Drug distributor McKesson and private equity firm Clayton Dubilier & Rice are nearing a deal to acquire infusion services provider Option Care Health in a transaction valued at more than $5 billion including debt, the Financial Times reported on Monday, citing people familiar with the matter.
Pennsylvania measles cases rise to 1,004 as outbreak spreads
Reuters | Posted Oct. 5 - 12:52 p.m. | Save Story
Pennsylvania's health department reported 1,004 measles cases as of Monday, as the state grapples with a fast-growing outbreak.
US and German scientists win Nobel medicine prize for work on light and brain
Johan Ahlander, Marie Mannes and Bhanvi Satija, Reuters | Updated Oct. 5 - 11:20 a.m. | Save Story
American Karl Deisseroth and Germans Peter Hegemann and Georg Nagel won the 2026 Nobel Prize in Physiology or Medicine on Monday for developing optogenetics, a technique that uses light to control individual nerve cells in the brain.
Nightmare on 13th earns national Halloween recognition
VideoTyrese Boone, KSL | Posted Oct. 5 - 10:03 a.m. | Save Story
A Salt Lake City haunted attraction is getting national recognition as one of America Haunts' Top 5 Fan Favorites for 2026.
CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis
Rajasik Mukherjee, Reuters | Updated Oct. 5 - 9:42 a.m. | Save Story
Australia's CSL said on Monday it had entered into an agreement with Swiss drugmaker Alentis Therapeutics to co-develop and co-promote a treatment for rare kidney and liver diseases, in a deal worth up to $1.6 billion, excluding development funding.
Gate Bioscience expands Lilly drug discovery deal worth more than $870 million
Reuters | Updated Oct. 5 - 7:54 a.m. | Save Story
Gate Bioscience said on Monday it expanded a research and licensing agreement with Eli Lilly to develop treatments targeting disease-causing proteins, in a deal potentially worth more than $870 million.
Alector soars as Roche licenses Parkinson's therapy for up to $1.27 billion
Reuters | Updated Oct. 5 - 7:54 a.m. | Save Story
Swiss drugmaker Roche will pay up to $1.27 billion to license Alector's experimental treatment for Parkinson's disease, the US biotech said on Monday, sending its shares surging 72% in premarket trading.
